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Macroautophagy (hereafter referred to as autophagy) is a housekeeping process consti-
tutively executed at basal level in all cells to promote cellular homeostasis by regulating 
organelle and protein turnover. However, autophagy deregulation caused by several 
stress factors, such as hypoxia, is prevalent in many cancers. It is now well established 
that autophagy can act as tumor suppressor or tumor promoter depending on tumor 
type, stage, and genetic context. In developed tumors, autophagy promotes the sur-
vival of cancer cells and therefore operates as a cell resistance mechanism. Emerging 
evidence point to the prominent role of autophagy in disabling the antitumor immune 
response by multiple overlapping mechanisms leading to tumor escape from immune 
cell attack mediated by both natural killer cells and cytotoxic T-lymphocytes. Such a role 
has inspired significant interest in applying anti-autophagy therapies as an entirely new 
approach to overcome tumor escape from immune surveillance, which constitutes so far 
a major challenge in developing more effective cancer immunotherapies. In this review, 
we will summarize recent reports describing how tumor cells, by activating autophagy, 
manage to hijack the immune system. In particular, we will focus on the emerging role of 
hypoxia-induced autophagy in shaping the antitumor immune response and in allowing 
tumor cells to outmaneuver an effective immune response and escape immunosurveil-
lance. In keeping with this, we strongly believe that autophagy represents an attractive 
future therapeutic target to develop innovative and effective cancer immunotherapeutic 
approaches.
Keywords: autophagy, hypoxia, antitumor immune response, tumor microenvironment, Natural Killer cells, 
Cytotoxic T Lymphocytes, chloroquine and immunological checkpoint-based immunotherapy
iNTRODUCTiON
Autophagy and Hypoxia
Under physiological conditions, autophagy is executed at low level to degrade damaged proteins 
and/or organelles in order to sustain metabolism and cell homeostasis. The level of basal autophagy 
varies depending on the tissue type and some tissues are particularly dependent on autophagy 
(e.g., brain, liver, and muscle) (1). It is now generally appreciated that autophagy is deregulated in 
some pathological conditions including cancer and it seems that the role of autophagy in cancer is 
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context and circumstance-dependent (2). Thus, autophagy sup-
presses tumor progression by limiting chromosomal instability 
(3); however, established tumors appear to utilize autophagy in 
order to survive periods of metabolic or hypoxic stress (3). In 
line with its role in sustaining viability and conferring stress tol-
erance, targeting autophagy has inspired significant interest for 
mitigating tumor growth and/or restoring response to anticancer 
therapies. Consistent with the part of autophagy in promoting 
tumor progression, it has been shown that targeting autophagy 
reduces cell migration and invasion in  vitro and attenuates 
metastasis in vivo in a breast cancer mouse model by promoting 
focal adhesion disassembly through targeted degradation of 
paxillin (4). Furthermore, several new studies have reported 
that autophagy activation plays also a major role in tumor 
immunity. Autophagy enhances tumor antigens processing and 
presentation thereby promoting adaptive antitumor immunity. 
In antigen-presenting cells (APC), autophagy promotes antigen 
presentations by major histocompatibility complexes (MHC). 
Such antigens presented by MHC class II and I are recognized 
by CD4+ and CD8+ T cells, respectively, in order to induce 
specific cytotoxic T-lymphocyte (CTL)-mediated immune 
response. Thus, autophagy allows the traffic of engulfed antigens 
to endosomes, where they are digested by cathepsins in order to 
be loaded onto MHC class II molecules and translocate to the 
plasma membrane to be finally presented to CD4+ T cells (5). 
Based on the role of autophagy in antigen presentation and pro-
cessing, it has been proposed that autophagy plays a beneficial 
role for the induction of antitumor immunity. In this context, 
hypoxia has been reported to increases tumor cell shedding of 
MHC class I resulting into increased resistance to natural killer 
(NK)-mediated lysis (6) via increased expression of ADAM10 
(7). The role of autophagy in antigen processing and presentation 
was reported in several comprehensive reviews (8–12) and will 
not be the subject of this review. However, emerging evidence 
strongly suggest that autophagy shows its worst facet when 
induced within the hypoxic tumor microenvironment (13). 
Indeed, autophagy impairs the antitumor immune responses 
mediated by CTL and NK cells and has been reported to enhance 
the immunosuppressive properties of myeloid-derived suppres-
sor cells (MDSCs). These issues will be discussed in more detail 
in the present review.
It is now well established that hypoxia develops due to a mis-
match between tumor growth and neovascularization. Cellular 
responses to hypoxia are mediated by hypoxia-inducible factor 
(HIF) family of transcription factors. Both HIF-1 and HIF-2 are 
composed of two subunits: an O2 regulated subunit (HIF1-α and 
HIF2-α) and a constitutively expressed subunit (HIF1-β and 
HIF2-β) (14). In the presence of oxygen, HIF-1α is hydroxylated 
by prolyl hydroxylase domain protein 2 (PHD2) on a proline 
residue leading to an interaction with the Von Hippel-Lindau 
(VHL) protein. Therefore, HIF-1α is polyubiquitylated and 
consequently targeted for degradation by the ubiquitin protea-
some system. Under hypoxic conditions, HIF-1α is stabilized, 
accumulated in the cytoplasm, and then translocated to the 
nucleus where it can form a heterodimer complex with HIF-1β. 
Finally, HIF-1 binds to hypoxia response elements (HREs) on 
the chromatin in order to induce the transcription of more than 
300 genes, involved in many biological processes, including 
angiogenesis, cell survival, metastasis, stem cell-like phenotype, 
and immune escape (15).
Three major pathways have been reported to induce autophagy 
under hypoxia. Briefly, HIF-1α-mediated induction of the expres-
sion of the BH3-only protein Bcl-2/adenovirus E1B 19 kDa-inter-
acting protein 3 (BNIP3) and the related protein, BNIP3L (16). 
BNIP3 and BNIP3L disrupt the autophagy inhibitory complex 
between Beclin1 (BECN1) and B-cell lymphoma 2 (Bcl-2) and 
activate autophagy in hypoxic cells, which operate as an adaptive 
survival response during prolonged hypoxia (Figure  1) (17). 
Autophagy can also be activated by endoplasmic reticulum (ER) 
stress in cancer cells. Indeed, ER stress stimulates the assembly of 
the pre-autophagosomal structures, the formation of autophago-
somes, and the transport to the vacuoles in an autophagy-related 
gene (ATG) dependent manner (18). Autophagy can also be 
induced in hypoxic cells subjected to metabolic stress through 
the activated adenosine monophosphate-activated protein kinase 
(AMPK). This leads to the initiation of autophagy both directly 
and indirectly by inhibiting the mammalian target of rapamycin 
(mTOR) (19, 20).
immune Checkpoints and Hypoxia
Immune checkpoint-based cancer immunotherapy has now 
emerged as a promising revolutionary treatment for many can-
cers including, but not limited to, melanoma, lung cancer, kidney 
cancer, bladder cancer, prostate cancer, and lymphoma (21). In 
the near future, immune checkpoint-based cancer immuno-
therapies will most probably join the ranks of surgery, radia-
tion, chemotherapy, and targeted therapy as a pillar of classical 
anticancer therapies. Ipilimumab (anti-CTLA-4) was approved 
in 2011, and pembrolizumab and nivolumab (anti-PD-1) were 
approved in 2014 by U.S. Food and Drug Administration (FDA) 
for the treatment of melanoma. These antibodies will soon be 
approved for treatment of patients with lung cancer, kidney can-
cer, and many other tumor types. The fact that these antibodies 
do not target tumor cells, but rather remove inhibitory signals 
on antitumor T cells have led to durable clinical responses in 
some patients (21).
Programed death 1 (PD-1) is an inhibitory receptor expressed 
mostly on activated T cells as well as other immune cells, and 
its expression is associated with T cell exhaustion. PD-1 has two 
ligands, Programed death-ligand 1 and 2 (PD-L1 and PD-L2). 
The interaction between PD-1 and its ligands sends a negative 
signal to T cells to dampen the antitumor immune response. 
Antibody-based blockade of PD-1 was shown to enhance effec-
tor T cell responses and induce T cell–mediated tumor rejection 
in some mouse models (22). PD-1 or PD-L1 blockade has been 
proven to be successful in many cancers (21), and anti-PD-1 
antibodies have recently been approved for use in the United 
States and Asia. Hypoxia-inducible factors were shown to 
enhance the effector responses (including both costimulatory 
and inhibitory molecules) of VHL deficient CD8+ T cells (with 
constitutive HIFs) to persistent viral antigen (23). We and others 
have reported that HIF-1α (24) and HIF-2α (25) regulate PD-L1 
expression under hypoxia (Figure 2). Hypoxia through HIF-1α 
has been also shown to regulate functional CD137 (4-1BB) on 
FiGURe 1 | Autophagy induction in hypoxic melanoma cells. Left image represents B16-F10 tumor section transplanted in C57BL/6 mouse. Tumor section 
was stained with Pimonidazole to illustrate hypoxic zones (in green). Blood vessels were stained with anti-CD31 (red) and nuclei with DAPI (blue). Right image is a 
schematic representation of tumor showing normoxic tumor cells close to the blood vessel (yellow) and hypoxic tumor cells (blue) at the periphery. In B16-F10 
mouse melanoma, autophagy is selectively induced in hypoxic zones. Lower image represents the mechanism underlying the activation of autophagy by hypoxia. In 
hypoxic cells, hypoxia-dependent activation of HIF-1α upregulates BNIP3 and BNIP3L by binding to their promoter regions. Both of these BH3-only proteins (BNIP3 
and BNIP3L) disrupt the complex between Beclin1 and Bcl-2, leading to the induction of autophagy.
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tumor-infiltrating T lymphocyte (26) and more recently soluble 
CD137 in malignant tumor cells (27).
Indeed, we first found a differentially higher expression of 
PD-L1 on tumor-infiltrating MDSCs as compared to splenic 
MDSCs (24) and hypoxia dramatically and significantly increased 
the percentage of PD-L1 positive MDSCs isolated from spleen 
in different tumor-bearing mice. We further provided evidence 
that HIF-1α is a major regulator of PD-L1 mRNA and protein 
expression, and that HIF-1α regulates the expression of PD-L1 by 
binding directly to the HRE-4 in the PD-L1 proximal promoter. 
The immune suppressive function of MDSCs, enhanced under 
hypoxia, was abrogated following PD-L1 blockade and hypoxia-
induced upregulation of interleukin-6 and 10 (IL-6 and IL-10) 
in MDSCs was significantly attenuated after PD-L1 block (24).
More recently, we showed that tumors from clear cell renal 
cell carcinoma (ccRCC) patients displaying VHL biallelic 
FiGURe 2 | Hypoxia via HiF-1α and HiF-2α regulates the expression of PD-L1 expression on tumor cell and MDSCs. The upper part represents the 
mechanism by which HIF-2α regulates the expression of PD-L1 in ccRCC tumor cells. Due to mutated VHL in ccRCC tumors, HIF-2α is constitutively stabilized and 
activated. HIF-2α translocates to the nucleus, binds to the HRE-4 in human PD-L1 promoter, and upregulates its expression. Whether this PD-L1 confers resistance 
to ccRCC sensitivity to antitumor effector cells remains to be investigated. The lower part represents the mechanism by which hypoxia via HIF-1α regulates the 
expression of PD-L1 in MDSCs. Similarly, stabilized HIF-1α in MDSCs isolated from tumors bound directly to the HRE-4 in the PD-L1 proximal promoter in MDSCs. 
The immune suppressive function of MDSCs, enhanced under hypoxia, was abrogated following PD-L1 blockade and hypoxia-mediated upregulation of IL-6 and 
IL-10 in MDSCs was significantly attenuated after PD-L1 blockade.
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inactivation (i.e., loss of function) exhibit a significant increase 
in PD-L1 expression as compared to ccRCC tumors carrying one 
VHL wild-type allele. Using the inducible VHL 786-O-derived 
cell lines with varying HIF-2α stabilization levels, we showed that 
PD-L1 expression levels positively correlate with VHL mutation 
and HIF-2α expression. Targeting HIF-2α decreased PD-L1 
while HIF-2α overexpression increased PD-L1 mRNA and 
protein levels in ccRCC cells. Interestingly, chromatin immuno-
precipitation and luciferase assays revealed a direct binding of 
HIF-2α to a transcriptionally active HRE in the human PD-L1 
proximal promoter in 786-O cells. In conclusion, VHL mutations 
positively correlate with PD-L1 expression in ccRCC and may 
influence the response to ccRCC patients to anti-PD-L1/PD-1 
immunotherapy (25).
eFFeCT OF AUTOPHAGY ON ANTiTUMOR 
iMMUNe ReSPONSeS
The role of cancer cell-associated autophagy in the modulation 
of the antitumor immune response takes place at different levels. 
First, autophagy may act at early step of cancer development, 
thus regulating the immune surveillance in the context of tumo-
rigenesis. Second, at later stage of cancer, the autophagy process 
was identified as an important modulator of the tumor cell 
proteome and secretome, allowing cancer cells to communicate 
with neighboring cells in the tumor microenvironment. Finally, 
cancer cell-associated autophagy may also acts as an intrinsic 
resistance mechanism evolved by tumor cells to overcome 
immune cell attack. Mounting evidence in the literature suggests 
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that depending on the context, the cancer model, and the type of 
stressor (e.g., hypoxia, chemotherapy), autophagy might either 
assist or prevent anticancer immunity.
Autophagy Modulates the immune 
Surveillance during Tumorigenesis
Autophagy serves as an adaptive response during period of stress 
by maintaining cellular integrity and metabolic homeostasis. 
Extensive works coming from Eileen White’s group have dem-
onstrated the crucial role of autophagy in cancer tumorigenesis. 
Notably, autophagy process actively contributes to elimination of 
source of genotoxic stress in order to maintain genomic integrity 
(28–30). However, autophagy inhibition may halt tumorigenesis 
not only by affecting cancer cell metabolism and proliferation 
per  se but also by enhancing the antitumor immunosurveil-
lance. The recent study of Rao et al. illustrated the complex role 
of autophagy in either tumorigenesis or tumor progression 
depending on the stage of the disease (31). Inactivation of Atg5-
dependent autophagy increased the number of tumor foci and 
favored the progression from hyperplasia to adenoma in a murine 
model of lung cancer (with KrasG12D mutation). However, in 
later stage of the disease, disabled autophagy reduced the pro-
gression from adenoma to adenocarcinoma. Immunoprofiling 
of early pulmonary lesions indicated that autophagy inactivation 
did not alter the global infiltration of the CD3ε+ T cells, but the 
amount of infiltrating Foxp3+ regulatory T cells (Tregs), which 
was increased in autophagy-deficient tumor. The authors clearly 
demonstrated that inactivation of autophagy in pneumocytes 
carrying a Kras mutation triggered a local expansion of Tregs 
cells, which control lung tumor initiation. This study established 
a cause-effect relationship between defective autophagy and infil-
tration of immunosuppressive Tregs cells. Other studies stated 
that autophagy inhibition may hamper tumorigenesis also by 
enhancing antitumor immunosurveillance. Recently, Levy et al. 
showed that conditional inactivation of the autophagy gene Atg7 
in intestinal epithelial cells (IECs) suppresses the development of 
precancerous lesions in Apc mutant mice (32). The authors dem-
onstrated that CD8+ T cells were essential effectors of the antitu-
mor immune response mediated by the inhibition of autophagy. 
Autophagy inactivation in IECs favored the infiltration and the 
expansion of interferon (IFN)-producing CD8+ T cells in the 
intestinal mucosa and participated in their priming. Moreover, 
Atg7 deficiency endorsed a CD4+ Th1 signature, which is associ-
ated with a good outcome in patients with colorectal cancer (33). 
However, Tregs infiltration was also induced, but in contrast to 
most studies, Tregs did not show immunosuppressive proper-
ties in those experimental conditions. Interestingly, this study 
reported that autophagy deficiency in IECs influenced intestinal 
microbiota, which is a prerequisite for an efficient anticancer 
immune response (32). In addition, Wei et al. have reported that 
conditional deletion of the ULK1-associated protein FIP200 in a 
PyMT-driven breast cancer murine model reduced the initiation 
of mammary intraepithelial neoplastic lesions and altered tumor 
progression by enhancing antitumor immune surveillance. 
FIP200-deficient tumor cells showed an upregulated expression 
of genes implicated in IFN signaling and an increased production 
of the chemokine CXCL10 that may favor infiltration of CD8+ 
T lymphocytes. This study, once again, showed that CD8+ T cells 
are crucial effectors of the autophagy-induced immunomodula-
tion, as depletion of CD8+ T cells with selective antibodies 
restored mammary tumor initiation and progression (34, 35).
The Dual immunomodulatory Role of 
Autophagy induction in Cancer Cells
Autophagy Influences the Adaptive Antitumor 
Immunity
The importance of autophagy was also highlighted during 
tumor progression to late stage of the disease. Autophagy acts 
as a pro-survival mechanism allowing cancer cells to overcome 
stress conditions. However, cells that fail to adapt stress will use 
autophagy to release specific signaling molecules allowing the 
immune clearance of damaged cells. Thus, the concept of immu-
nologic cell death (ICD) has rapidly emerged as an important 
feature determining an effective antitumor immune response 
(36). ICD is characterized by the rapid surface exposure of 
calreticulin (ecto-CRT), the secretion of ATP, and the release of 
apoptotic proteins as high mobility group box 1 (HMGB1), which 
are excellent immunogenic signals (36, 37). Bona fide ICD leads 
to increased maturation and stimulation of dendritic cells (DCs), 
which are required for robust T cells response. An increasing 
amount of evidence suggests that autophagy plays a crucial role 
during ICD by modulating the cancer cell secretome and surface 
proteome following stress or cell death induction.
In response to chemotherapeutic stress, autophagy-deficient 
cells displayed ecto-CRT, released HMGB1 but secreted less ATP 
than autophagy-competent cells. Michaud et  al. showed that 
autophagy contributes to immunogenic signaling in vivo through 
the secretion of ATP. Impairment of autophagy in mitoxantrone 
(MTX)-treated murine colorectal carcinoma cells decreased the 
intratumoral recruitment of DCs and T cells when injected in 
immunocompetent mice. Artificial increase of intratumoral 
ATP restored the immunogenicity of MTX-treated autophagy-
deficient cells, confirming that activation of autophagy following 
chemotherapy-induced ICD facilitates ATP secretion and the 
intratumoral accumulation of DCs and T lymphocytes (38).
Another important immunostimulatory signal that requires 
autophagy is the exposure of CRT at the cancer cell surface. 
Ecto-CRT triggers the engulfment of the damaged cells by 
macrophages. It has been described by Garg et al. that exposure 
of CRT is abolished in cancer cells when chaperone-mediated 
autophagy is impaired (39). In contrast to expectations, the same 
authors demonstrated that ER stress-induced autophagy, follow-
ing photodynamic therapy, negatively regulated CRT surface 
exposure without affecting ATP secretion. Inhibition of ER 
stress-induced autophagy, by knocking down Atg5 in cancer cells, 
improved the maturation of IL-6 secreting DCs, and thus trig-
gered proliferation of IFNγ-producing CD4+ and CD8+ T cells. 
Moreover, inactivation of autophagy in untreated melanoma cells 
increased CRT surface exposure, suggesting that basal autophagy 
in cancer cells may support immune escape (39, 40).
The pro-inflammatory role of autophagy may also be related to 
the protein HMGB1. In one hand, the cytosolic form of HMGB1 
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is able to bind to BECN1, which further leads to the formation of 
autophagosomes. On the other hand, secreted HMGB1 can also 
trigger autophagy through the binding to the RAGE receptor 
(receptor for advanced glycation endproducts) (41, 42). Once 
released outside the cell, HMGB1 has been shown to own both 
immunosuppressive and immunostimulatory properties (43). 
Production of HMGB1 by colon cancer cells also decreases the 
differentiation of DCs. In line with these experimental results, 
high HMGB1 levels in primary tumor tissues correlate with 
low intratumoral CD205+ DCs (44). Conversely, tumor cell-
derived HMGB1 was shown to suppress CD8+ T cells antitumor 
immunity through the induction of IL-10-producing Tregs (45). 
Recently, Ladoire et  al. provided evidence that cytoplasmic 
microtubule-associated protein 1A/1B-light chain 3 (LC3II), 
and nuclear HMGB1 expression may influence the nature of the 
immune infiltrate in breast cancer. Thus, the absence of LC3II 
correlated with intratumoral, but not peritumoral, infiltration of 
Foxp3+ Tregs, CD68+ tumor-associated macrophages and less 
CD8+ T cytotoxic lymphocytes. Moreover, absence of HMGB1 
expression in the nuclei was associated with the increase in both 
intratumoral and peritumoral infiltration by Foxp3+ and CD68+ 
cells. Taken together, these results suggest that autophagy block-
ade or HMGB1 loss in breast cancer cells have a negative impact 
on the anticancer immune surveillance (46).
Autophagy has also emerged as a critical pathway for tumor 
antigen cross-presentation, which is determinant for the initia-
tion of an efficient adaptive immune response (47, 48). Autophagy 
actively participates in antigen sequestration and delivery to 
DCs for cross-priming of CD8+ T cells. Inhibition of autophagy 
in melanoma cells by knocking down BECN1 significantly 
reduced T cell proliferation in  vitro and in  vivo (47). 
Moreover, induction of autophagy by the vitamin E derivative 
α-tocopheryloxyacetic acid (α-TEA) in 3LL Lewis lung carci-
noma and 4T1 mammary carcinoma cells led to the release of 
antigen-containing autophagosomes that increase CD8+ T cells 
activation (49). Interestingly, tumor antigens packaged into 
autophagosomes were more efficient for T cells activation than 
soluble antigens (47).
It is now clearly established that autophagy activation in 
cancer cells is an effective way to communicate with the tumor 
microenvironment. However, accumulating observations 
have highlighted that autophagy activation may also serve 
as an intrinsic mechanism of resistance evolved by cancer 
cells to overcome immune cell attack (Figure 3) (13). Noman 
et  al. demonstrated that hypoxia-induced autophagy acts as 
a mechanism of resistance to cytotoxic T cells-mediated lysis 
through the activation of the signal transducer and activator of 
transcription 3 (STAT3) signaling (50, 51). Our group provided 
for the first time direct evidence between autophagy and the 
regulation of STAT3 signaling. Inactivation of autophagy, by 
specific silencing of BECN1 or ATG5, restored lung cancer cell 
sensitivity to T cells lysis, which was associated with a decrease 
in hypoxia-induced pSTAT3. Interestingly, in vivo administra-
tion of the autophagy inhibitor hydroxychloroquine (HCQ) 
with a tyrosinase-related protein-2 (TRP2) peptide-based 
vaccination strategy led to a significant reduction of melanoma 
growth compared to vaccine or HCQ treatment alone. Although 
the clear link between autophagy activation and induction of 
STAT3 signaling remains to be elucidated, it has been clearly 
established that STAT3 is an important mediator in the crosstalk 
between tumor and immune cells (Figure 3) (52). The aberrant 
STAT3 signaling in tumor cells can suppress the expression of 
pro-inflammatory danger signals (e.g., IFNγ, TNF, CXCL10), 
while induces the expression of immunosuppressive factors 
(e.g., VEGF, IL-10) that inhibit DCs maturation (53).
More recently, studies have reported that tumor cells under-
going epithelial-to-mesenchymal transition (EMT) escape from 
T cell-mediated lysis. During EMT, phenotypic changes occur 
and expression of certain tumor antigens is downregulated, 
thus restraining T cells specific recognition and killing (54). The 
consequence of EMT on immune system is likely to be dependent 
on the cancer cell origin. Indeed, depending on the tumor type, 
EMT may either avoid proliferation/stimulate apoptosis of NK, B, 
and T cells or promote expansion of Tregs (55). The relationship 
between autophagy and EMT is not clearly established so far. 
However, it has been reported that acquisition of mesenchymal 
phenotype in breast cancer cell was associated with modifica-
tion of autophagy gene expression, indicating a concomitant 
autophagy activation in those cells (56). EMT induction through 
the overexpression of snail homolog 1 (SNAI1) in MCF7 breast 
cancer cell line led to autophagy induction through the upregu-
lation of BECN1. These observations indicated that autophagy 
activation is a downstream target of EMT. Thus, targeting EMT-
induced autophagy in mesenchymal cells was sufficient to restore 
T cell-mediated lysis without affecting cell morphology and the 
expression of EMT markers (Figure 3) (57, 58).
Autophagy Modulates the Innate Antitumor  
Immune Response
Our group also provided evidence that autophagy induction in 
hypoxic breast cancer cells influences the innate antitumor immu-
nity mediated by NK cells (59, 60). We demonstrated in vitro that the 
NK-derived serine protease granzyme B (GZMB) was selectively 
degraded into autophagosomes in hypoxic breast cancer cells, in 
which autophagy is induced. Selective inhibition of autophagy, by 
silencing BECN1 or ATG5 in hypoxic cancer cells, restored the 
susceptibility to NK-mediated lysis. This concept was validated 
in vivo by using two syngeneic models of tumor transplantation. 
We showed that inhibition of autophagy in cancer cells contrib-
uted to a significant reduction of the tumor volume by improving 
elimination by NK cells (59). In line with this study, the role of 
autophagy in modulating the NK-mediated antitumor immune 
response was extended to ccRCC. The VHL-mutated ccRCC, 
exhibiting high autophagy rate, was less susceptible to NK-derived 
GZMB than VHL-corrected ccRCC. This resistance required 
the stabilization of HIF-2α and the subsequent overexpression 
of the autophagy sensor inositol 1, 4, 5-trisphosphate receptor, 
type 1 (ITPR1). Both inhibition of BECN1 or ITPR1 in VHL-
mutated ccRCC cells restored NK-mediated killing (Figure  3) 
(61, 62).
Additionally, activation of autophagy in cancer cells was shown 
to be implicated in the destabilization of the interaction between 
target and effector cells. Hypoxia-induced autophagy was identi-
fied as a selective degradation pathway of the gap junction protein 
FiGURe 3 | Tumor cells with activated autophagy defend themselves from NK- and CTL-mediated killing by diverse mechanisms. Hypoxia and/or EMT 
activation induces autophagy in tumor cells. A summary of diverse mechanisms by which autophagy activation leads to the acquisition of tumor cell resistance to 
CTL and NK-mediated lysis. Hypoxia-induced autophagy in cancer cells acts as an intrinsic resistance mechanism to NK-mediated lysis through the selective 
degradation of the NK-derived serine protease granzyme B (GZMB) (upper right). Moreover, the selective degradation of the gap junction protein connexin 43 (Cx43) 
is also implicated in the destabilization of the interaction between tumor and NK cells (lower right). The activation of the signal transducer and activator of 
transcription 3 (STAT3) signaling along with autophagy activation in tumor cells leads to the acquisition of resistance to CTL-mediated lysis (upper left). Autophagy 
activation, following epithelial-to-mesenchymal (EMT) induction, leads to BECN1 overexpression, and is sufficient to overcome CTL-mediated attack (lower left).
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connexin 43 (Cx43) that renders the melanoma cells resistant to 
NK cells-mediated attack. Expression of a non-degradable form 
of Cx43 or targeting autophagy in hypoxic cancer cells restored 
the accumulation of Cx43 at the immunological synapse and 
improved NK cells-mediated lysis (Figure 3) (63).
Finally, autophagy induction is known to be closely related 
to the pathway of exosome secretion (64). In addition, hypoxia 
was described to enhance exosome release by cancer cells (65). 
Exosomes are small extracellular vesicles of endosomal origin, 
are released by all cell types, and constitute a new component 
of cell–cell communication. They carry membrane proteins, 
enzymes, chaperone proteins, but also DNA and various types 
of RNA (mRNA, lncRNA, and miRNA). Microvesicles derived 
from hypoxic cells were shown to induce an invasive and pro-
metastatic phenotype (66, 67) and to inhibit the immune response 
(68). In particular, we showed that vesicles produced by hypoxic 
cancer cells inhibit NK cell functions. Following their uptake, the 
vesicles transfer TGF-β1 to NK cells, decreasing expression of the 
activating receptor NKG2D on the cell surface. We also identified 
high levels of miR-23a in hypoxic vesicles that directly targets the 
expression of the marker of degranulation CD107a in NK cells. 
Those two immunosuppressive mechanisms inhibiting NK cell 
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functions strongly contribute to decrease the antitumor immune 
response (68).
AUTOPHAGY iNHiBiTiON ALONG wiTH 
New COMBiNATORiAL iMMUNe 
CHeCKPOiNT BLOCKeRS
Immune checkpoint-based immunotherapy revolution has just 
started, and new combination strategies with potent curative 
potential are currently emerging (22). In spite of outstanding and 
encouraging response, the majority of patients treated with anti-
PD-1/PD-L1 monotherapies have partial tumor regressions and 
they fail to achieve higher objective responses. This suggests that 
in order to obtain durable tumor regressions, there is a need for 
combination therapies along with anti-PD-1/PD-L1 monothera-
pies. Several reports using various preclinical animal models have 
shown that combination therapies based on immune checkpoint 
blockers are strongly synergistic along with classical cancer 
therapies (including chemotherapy, tyrosine kinase inhibitors, 
radiotherapy, and vaccines) (21).
The combination of both anti-CTLA-4 and anti-PD1 has been 
shown to be twice as effective as either treatment alone in the 
rejection of B16-F10 melanoma tumors. This combination ther-
apy increased T-effector to MDSC ratio and also increased IFN-γ/
TNF-α double producing CD8+ T cells. Finally, PD-1 and CTLA-4 
combination blockade expanded infiltrating T cells and reduced 
regulatory T and myeloid cells within B16 melanoma tumors (69). 
Similarly, in mouse models of colon carcinoma (CT26 cell line) 
and ovarian carcinoma (ID8-VEGF cell line), dual block (both 
anti-PD1 and anti-CTLA-4) combined with tumor vaccine leads 
to effective tumor rejection through the restoration of effector T 
cell function (70). More interestingly, it has been reported that the 
combination of anti-4-1BB and anti-PD-1 is more effective than 
that of anti-PD-1/anti-LAG-3 in suppressing B16-F10 melanoma 
tumor growth without adjuvant or vaccination (71). In a phase 1 
clinical trial with advanced melanoma patients, the combination 
of anti-CTLA-4 and anti-PD-1 increased the response rate up to 
53% patients with severe treatment-related adverse events (72). 
Autophagy inhibitor CQ is currently used in several clinical tri-
als to sensitize tumor cells to radio and chemotherapy. We have 
previously shown that, by simultaneously boosting the immune 
system and inhibiting autophagy using CQ, we can significantly 
enhance the therapeutic efficacy of antigen-based cancer vaccines 
in B16 tumors (51). In this regard, a combination of autophagy 
inhibition and immune checkpoint-based immunotherapy would 
probably revert immune suppressive microenvironment and pro-
mote additional tumor regression. Although anti-CTLA-4 and 
anti-PD-1 are currently the focus of clinical attention, it is likely 
that blockade of additional checkpoints will result in even further 
clinical activity as multiple checkpoints appear to be co-expressed 
with PD-L1 and PD-1 on the same tumors (21, 22).
CONCLUDiNG ReMARKS
Cancer immunotherapy based on immune checkpoint inhibitors 
marks a turning point in cancer treatment since it revolution-
izing the way we treat cancer. Immune checkpoint-based 
immunotherapies have shown great promise for a subset of 
cancer patients. However, safe, robust, and attentive combination 
therapies are still needed to bring the benefit of cancer immuno-
therapy to a larger class of cancer patients. While searching for 
an optimal strategy of combinatorial immunotherapy, we have to 
keep in mind that different immune checkpoints are expressed 
simultaneously on both tumor cells, stromal cells, and different 
immune cells. Furthermore, there is a differential expression of 
both inhibitory and activating receptors on different immune 
cells within the tumor microenvironment. Autophagy remains to 
be a pretty interesting combination target while developing novel 
and cutting edge cancer immunotherapeutic approaches.
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